liveBook · Manning

Selectivity

As explained in Build AI Drug Discovery Pipelines

Selectivity is the extent to which a compound binds to or affects its intended target relative to other proteins or biological targets.

Selectivity measures how strongly a compound binds to its intended target relative to other proteins or biological targets. High selectivity can reduce unintended effects on organs and biological processes, making it an important lead-optimization property alongside potency, safety, and bioavailability. section 1.4.2

Kinase selectivity is difficult because ATP-binding sites are highly conserved across the kinase family. An inhibitor aimed at one kinase may therefore inhibit many others; its cross-reactivity profile helps interpret efficacy and potential toxicity. section 11.1.1

Selectivity connects to practical discovery decisions:

  • Lead optimization improves selectivity while retaining a compound’s core molecular structure and also considers potency, efficacy, safety, and ADMET properties. section 1.4.2
  • A selectivity profile records how a molecule behaves across multiple targets rather than measuring only its intended interaction. section 11.1.1

DAVIS kinase-selectivity benchmark

The DAVIS dataset experimentally screened 72 kinase inhibitors against 442 kinases, producing 30,056 drug–target pairs. It records binding affinity as Kd in nanomolar units; machine-learning workflows convert Kd to pKd, where higher values indicate stronger binding. Comparing one inhibitor across kinases makes its selectivity and cross-reactivity visible. section 11.1.1

Figure 11.2 Distribution of pKd Affinity Values in the DAVIS Dataset and KIBA scores in the KIBA Dataset. For the DAVIS dataset, we observe a very large, sharp peak visible at the y-value of 5, with a much smaller, broader distribution of values between 6 and 10.

Use the affinity-distribution figure to inspect the concentration of DAVIS pKd values and the broader range of measured binding strengths. section 11.1.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Defines selectivity, explains kinase cross-reactivity, and reaches dataset-level Kd-to-pKd representation without detailing binding mechanisms.
Examples
Uses kinase-inhibitor screening across 442 kinases, the DAVIS dataset, Kd measurements, pKd conversion, and affinity distributions.
What it assumes
Explains the core meaning of selectivity before applying it to proteins, kinase families, binding affinity, and drug discovery.
What you can do after
Evaluate kinase-inhibitor cross-reactivity and interpret binding-affinity data as evidence about selectivity.
How it connects
Ties selectivity to lead optimization, potency, safety, bioavailability, binding affinity, therapeutic index, and off-target effects.

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.